CA2116130A1 - Diagnostic et traitement de la maladie de parkinson - Google Patents
Diagnostic et traitement de la maladie de parkinsonInfo
- Publication number
- CA2116130A1 CA2116130A1 CA002116130A CA2116130A CA2116130A1 CA 2116130 A1 CA2116130 A1 CA 2116130A1 CA 002116130 A CA002116130 A CA 002116130A CA 2116130 A CA2116130 A CA 2116130A CA 2116130 A1 CA2116130 A1 CA 2116130A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- mao
- parkinson
- individual
- haplotype
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
- C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03004—Monoamine oxidase (1.4.3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76230291A | 1991-09-20 | 1991-09-20 | |
| US07/762,302 | 1991-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2116130A1 true CA2116130A1 (fr) | 1993-04-01 |
Family
ID=25064666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002116130A Abandoned CA2116130A1 (fr) | 1991-09-20 | 1992-08-17 | Diagnostic et traitement de la maladie de parkinson |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0666745A4 (fr) |
| JP (1) | JPH07501518A (fr) |
| AU (1) | AU2492192A (fr) |
| CA (1) | CA2116130A1 (fr) |
| WO (1) | WO1993005783A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783680A (en) * | 1993-10-06 | 1998-07-21 | The General Hospital Corporation | Genetic diagnosis and treatment for impulsive aggression |
| WO2002010454A2 (fr) * | 2000-07-28 | 2002-02-07 | Genaissance Pharmaceuticals, Inc. | Haplotypes du gene alas2? ¿ |
| WO2002012561A2 (fr) * | 2000-08-03 | 2002-02-14 | Genaissance Pharmaceuticals, Inc. | Haplotypes du gene or1g1 |
| WO2002012498A2 (fr) * | 2000-08-04 | 2002-02-14 | Genaissance Pharmaceuticals, Inc. | Haplotypes du gene isl1 |
| WO2002012499A2 (fr) * | 2000-08-04 | 2002-02-14 | Genaissance Pharmaceuticals, Inc. | Haplotypes du gene ntf3 |
| WO2002012342A2 (fr) * | 2000-08-04 | 2002-02-14 | Genaissance Pharmaceuticals, Inc. | Haplotypes du gene edg4 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030570A (en) * | 1988-06-30 | 1991-07-09 | The Eunice Kennedy Shriver Center For Mental Retardation | DNA encoding and method of expressing human monoamine oxidase type A |
| WO1991018005A1 (fr) * | 1990-05-14 | 1991-11-28 | Duke University | Genes clones codant pour le recepteur de dopamine d¿1? |
-
1992
- 1992-08-17 CA CA002116130A patent/CA2116130A1/fr not_active Abandoned
- 1992-08-17 AU AU24921/92A patent/AU2492192A/en not_active Abandoned
- 1992-08-17 WO PCT/US1992/006746 patent/WO1993005783A1/fr not_active Ceased
- 1992-08-17 EP EP92918207A patent/EP0666745A4/fr not_active Withdrawn
- 1992-08-17 JP JP5506029A patent/JPH07501518A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1993005783A1 (fr) | 1993-04-01 |
| JPH07501518A (ja) | 1995-02-16 |
| EP0666745A1 (fr) | 1995-08-16 |
| AU2492192A (en) | 1993-04-27 |
| EP0666745A4 (fr) | 1995-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Comings et al. | Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse | |
| Gutiérrez et al. | Association analysis of the catechol O-methyltransferase gene and bipolar affective disorder | |
| US20030044797A1 (en) | Detection of CYP2D6 polymorphisms | |
| Ozelius et al. | Human monoamine oxidase gene (MAOA): chromosome position (Xp21-p11) and DNA polymorphism | |
| Comings | Why different rules are required for polygenic inheritance: lessons from studies of the DRD2 gene | |
| Hamilton et al. | Lack of genetic linkage or association between a functional serotonin transporter polymorphism and panic disorder | |
| Souery et al. | Association study of bipolar disorder with candidate genes involved in catecholamine neurotransmission: DRD2, DRD3, DAT1, and TH genes | |
| Kramer et al. | A locus for the nystagmus-associated form of episodic ataxia maps to an 11-cM region on chromosome 19p | |
| KR20000052680A (ko) | 후발성 진성 당뇨병으로 분리되는 미토콘드리아성 dna돌연변이 | |
| Maier-Dobersberger et al. | Diagnosis of Wilson's disease in an asymptomatic sibling by DNA linkage analysis | |
| US20060088874A1 (en) | Methods and kits for detecting mutations | |
| US20040248092A1 (en) | Methods of screening for parkinsons's disease | |
| Bandmann et al. | Mitochondrial DNA polymorphisms in pathologically proven Parkinson’s disease | |
| Geijer et al. | Tyrosine hydroxylase and dopamine D4 receptor allelic distribution in Scandinavian chronic alcoholics | |
| Nanko et al. | No association between Parkinson's disease and monoamine oxidase A and B gene polymorphisms | |
| Körner et al. | RFLP alleles at the tyrosine hydroxylase locus: no association found to affective disorders | |
| Girmen et al. | Relationship between platelet monoamine oxidase B activity and alleles at the MAOB locus | |
| CA2116130A1 (fr) | Diagnostic et traitement de la maladie de parkinson | |
| Schuback et al. | Screen for MAOA mutations in target human groups | |
| Nimgaonkar et al. | Negative association of schizophrenia with HLA DQB1* 0602: evidence from a second African-American cohort | |
| Bonneau et al. | No evidence of genetic heterogeneity in dominant optic atrophy. | |
| Nurnberger Jr et al. | Chromosome 6 workshop report | |
| Nanko et al. | Linkage studies between affective disorder and dopamine D2, D3, and D4 receptor gene loci in four Japanese pedigrees | |
| Balciuniene et al. | Linkage analysis of candidate loci in families with recurrent major depression | |
| US20030054381A1 (en) | Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |